Surgaid

SAD (Xiamen) Medical Equipment Co., Ltd. (hereinafter referred to as "Surgaid") was founded in 2010 and is a subsidiary of Dabot Medical (stock code: 002901). It is a medical device company specializing in the research, development, production, and sales of surgical medical devices. Since its establishment, Surgaid has placed high importance on talent cultivation, building a professional R&D team of hundreds of people and forming a solid technical barrier. It consistently adheres to independent research and development, creating numerous innovative surgical products with high technical content and excellent added value, successfully obtaining 110 invention patents. Committed to technological innovation, the company has established long-term stable industry-academia-research cooperation relationships with more than ten universities and research institutions at home and abroad, deeply exploring new technologies and products in surgery, injecting continuous momentum into the company’s development. Supported by the strong manufacturing capabilities of its headquarters, Surgaid is equipped with advanced production equipment from the United States, Japan, Germany, Switzerland, and other countries, building a digital management platform integrating design, technology, manufacturing, and quality control. It has successfully passed ISO13485, CE certification, and on-site inspections. Upholding meticulous craftsmanship and adhering to lean production, the company, with production capabilities rivaling international standards, has won excellent reputation and recognition through its superior product quality. Guided by clinical needs, Surgaid has built a diversified range of surgical instrument product lines, covering areas such as access series, stapling series, ligation series, ultrasonic scalpel series, insufflator series, and artificial intelligence. Through dedicated efforts, the market coverage rate of the company's access series products ranks among the top three in China for similar products and is exported to more than 10 countries and regions including South Korea, Chile, and the Netherlands, continuously gaining attention and recognition from domestic and international markets.